{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:40:01Z","timestamp":1748482801926,"version":"3.41.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.arteri.2015.05.002","type":"journal-article","created":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T11:58:09Z","timestamp":1436097489000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estatinas en la prevenci\u00f3n secundaria del ictus: nuevas evidencias del estudio SPARCL"],"prefix":"10.1016","volume":"28","author":[{"given":"Luis","family":"Castilla-Guerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Carmen","family":"Fern\u00e1ndez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"L\u00f3pez-Chozas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2015.05.002_bib0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.33588\/rn.4402.2006549","article-title":"Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevenci\u00f3n del ictus","volume":"44","author":"Castilla-Guerra","year":"2007","journal-title":"Rev Neurol."},{"key":"10.1016\/j.arteri.2015.05.002_bib0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arteri.2015.05.002_bib0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.05.002_bib0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2015.05.002_bib0110","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.arteri.2015.05.002_bib0115","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0120","first-page":"229","article-title":"Atorvastatin in stroke: A review of SPARCL and subgroup analysis","volume":"6","author":"Huisa","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.arteri.2015.05.002_bib0125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/01.wnl.0000327339.55844.1a","article-title":"Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack","volume":"72","author":"Chaturvedi","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.arteri.2015.05.002_bib0130","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1161\/STROKEAHA.107.513747","article-title":"Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study","volume":"39","author":"Goldstein","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0135","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0140","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(04)16146-1","article-title":"Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomized controlled trial","volume":"363","author":"Halliday","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.05.002_bib0150","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0155","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1161\/STROKEAHA.108.546135","article-title":"Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2015.05.002_bib0160","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.atherosclerosis.2008.09.008","article-title":"Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"204","author":"Amarenco","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2015.05.002_bib0165","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archneurol.2011.146","article-title":"Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type2 diabetes or metabolic syndrome: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"68","author":"Callahan","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.arteri.2015.05.002_bib0170","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/STROKEAHA.113.004229","article-title":"Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients","volume":"45","author":"Sirimarco","year":"2014","journal-title":"Stroke"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:22:08Z","timestamp":1748481728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916815000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0214916815000686"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2015.05.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estatinas en la prevenci\u00f3n secundaria del ictus: nuevas evidencias del estudio SPARCL","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2015.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}